Armata Pharmaceuticals, Inc.
ARMPNYSE
$4.51
↑ +19.9%Jul 17 close · end-of-day
Price
1Y↑ +91.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$164.8M
Enterprise Value
$160.0M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-14.8%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$282.6M
Free Cash Flow (TTM)
-$24.5M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
90.7%
ROIC
—
Debt / Equity
—
Net Cash
$4.8M
Return 1Y
+86.4%
Company profile
Armata Pharmaceuticals, Inc. focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PS03 for pneumonia.
- CEO
- Brian C. Varnum
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 70
- Headquarters
- California
- Website
- armatapharma.com
Management & directors
- Birx DeborahChief Executive Officer
- Kyme PierreChief Business Officer
Roles derived from SEC Form 4 filings.
Earnings
ARMP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$3.16↑ +1480.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$21.6M | -$23.8M | -$36.9M | -$40.9M | -$42.4M | -$36.6M |
| Net income | -$22.2M | -$23.2M | -$36.9M | -$69.0M | -$18.9M | -$173.8M |
| Diluted EPS | -$1.35 | -$0.96 | -$1.08 | -$1.91 | -$0.89 | -$4.80 |
| Operating cash flow | -$18.3M | -$23.6M | -$32.5M | -$47.4M | -$37.6M | -$25.8M |
| Free cash flow | -$19.1M | -$24.9M | -$34.7M | -$55.6M | -$39.4M | -$26.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$11.9M | -$9.8M | -$10.5M | -$8.2M | -$6.8M | -$7.8M | -$13.8M | -$8.8M |
| Net income | $9.0M | -$5.5M | $2.6M | -$6.5M | -$16.3M | -$26.7M | -$124.3M | -$115.3M |
| Diluted EPS | -$0.25 | -$0.15 | $0.20 | -$0.20 | -$0.45 | -$0.74 | -$3.41 | -$3.16 |
| Operating cash flow | -$10.2M | -$8.9M | -$7.9M | -$7.6M | -$7.2M | -$4.3M | -$6.7M | -$5.8M |
| Free cash flow | -$11.5M | -$9.2M | -$8.0M | -$7.7M | -$7.4M | -$4.5M | -$6.7M | -$5.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | Birx Deborah· Chief Executive Officer | Tax withholding | 14,041 | $4.26 | $59,814.66 | filing |
| 2026-03-14 | Birx Deborah· Chief Executive Officer | Tax withholding | 4,919 | $10.54 | $51,846.26 | filing |
| 2026-03-14 | Kyme Pierre· Chief Business Officer | Tax withholding | 1,030 | $10.54 | $10,856.20 | filing |
| 2025-07-10 | Birx Deborah· Chief Executive Officer | Tax withholding | 13,637 | $2.27 | $30,955.99 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.